Lexaria Bioscience Corp.
LEXXNASDAQHealthcare● Active
$0.65
+$0.01(+0.84%)
Market Cap$13329777
P/E Ratio—
52W High$1.55
52W Low$0.46
Lexaria Bioscience Corp. (LEXX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LEXX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 13, 2026EPS Actual
-$0.06
Est. -$0.10 · +40.0%
Revenue
$0.00B
Est. $0.00B · -60.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 13, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
LEXX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $4.26B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$4.26B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 13, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 13, 2026 | -$0.10 | -$0.06 | +40.0% | $0.00B | $0.00B | -60.0% |
| ▲ Q1 FY2026 | Jan 13, 2026 | -$0.13 | -$0.07 | +46.1% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 26, 2025 | -$0.16 | -$0.13 | +18.8% | $0.00B | $0.00B | +27.0% |
| ▼ Q3 FY2025 | Jul 14, 2025 | -$0.15 | -$0.21 | -40.0% | $0.00B | $0.00B | +27.0% |
| ▲ Q2 FY2025 | Apr 14, 2025 | -$0.16 | -$0.15 | +6.3% | $0.00B | $0.00B | +90.5% |
| ▼ Q1 FY2025 | Jan 10, 2025 | -$0.12 | -$0.16 | -33.3% | $0.00B | $0.00B | +83.9% |
| ▼ Q4 FY2024 | Nov 26, 2024 | -$0.11 | -$0.15 | -36.4% | $0.00B | $0.00B | -16.0% |
Q3 FY2026
Jul 13, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 13, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.10
EPS Surpr.
+40.0%
Revenue
$0.00B
Q1 FY2026
Jan 13, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.13
EPS Surpr.
+46.1%
Revenue
—
Q4 FY2025
Nov 26, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.16
EPS Surpr.
+18.8%
Revenue
$0.00B
Q3 FY2025
Jul 14, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.15
EPS Surpr.
-40.0%
Revenue
$0.00B
Q2 FY2025
Apr 14, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.16
EPS Surpr.
+6.3%
Revenue
$0.00B
Q1 FY2025
Jan 10, 2025Miss
EPS Actual
-$0.16
EPS Est.
-$0.12
EPS Surpr.
-33.3%
Revenue
$0.00B
Q4 FY2024
Nov 26, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.11
EPS Surpr.
-36.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q2 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q1 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q4 FY2026 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 13, 2026 | +40.0% | $0.91 | $0.98 | +7.69% |
| ▲ Q1 FY2026 | Jan 13, 2026 | +46.1% | $0.77 | $0.81 | +5.08% |
| ▲ Q4 FY2025 | Nov 26, 2025 | +18.8% | $1.08 | $1.12 | +3.70% |
| ▼ Q3 FY2025 | Jul 14, 2025 | -40.0% | $0.88 | $0.83 | -5.31% |
| ▲ Q2 FY2025 | Apr 14, 2025 | +6.3% | $1.35 | $1.41 | +4.44% |
| ▼ Q1 FY2025 | Jan 10, 2025 | -33.3% | $2.21 | $2.16 | -2.26% |
| ▼ Q4 FY2024 | Nov 26, 2024 | -36.4% | $2.15 | $2.13 | -0.93% |
| ▼ Q3 FY2024 | Jul 12, 2024 | -30.0% | $2.81 | $2.79 | -0.71% |
Q2 FY2026+7.69%
Report Date
Apr 13, 2026
EPS Beat/Miss
+40.0%
Price Before
$0.91
Price After
$0.98
Q1 FY2026+5.08%
Report Date
Jan 13, 2026
EPS Beat/Miss
+46.1%
Price Before
$0.77
Price After
$0.81
Q4 FY2025+3.70%
Report Date
Nov 26, 2025
EPS Beat/Miss
+18.8%
Price Before
$1.08
Price After
$1.12
Q3 FY2025-5.31%
Report Date
Jul 14, 2025
EPS Beat/Miss
-40.0%
Price Before
$0.88
Price After
$0.83
Q2 FY2025+4.44%
Report Date
Apr 14, 2025
EPS Beat/Miss
+6.3%
Price Before
$1.35
Price After
$1.41
Q1 FY2025-2.26%
Report Date
Jan 10, 2025
EPS Beat/Miss
-33.3%
Price Before
$2.21
Price After
$2.16
Q4 FY2024-0.93%
Report Date
Nov 26, 2024
EPS Beat/Miss
-36.4%
Price Before
$2.15
Price After
$2.13
Q3 FY2024-0.71%
Report Date
Jul 12, 2024
EPS Beat/Miss
-30.0%
Price Before
$2.81
Price After
$2.79
Avg Beat Reaction+5.23%
Avg Miss Reaction-2.30%
Beat Rate4 / 8 quarters
Largest Move+7.69% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LEXX ends December
Lexaria Bioscience Corp. (LEXX) most recently reported earnings on April 13, 2026 for Q2 FY2026, posting EPS of $-0.06 — beating the analyst consensus of $-0.10 by +40.0%. LEXX has beaten EPS estimates for 3 consecutive quarters. The next LEXX earnings date is expected around September 1, 2026.
Each quarter, investors track LEXX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LEXX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LEXX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LEXX earnings · 5 questionsLexaria Bioscience Corp.'s next earnings report is expected around September 1, 2026. LEXX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LEXX historically reports after market close (AMC).
LEXX earnings datewhen is LEXX earningsLEXX next earnings datewhen does LEXX report earningsLEXX earnings calendar
▸ Source: FMP · Lexaria Bioscience Corp. SEC filings · US GAAP · Lexaria Bioscience Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026